Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma

/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing...

Related Keywords

California ,United States ,University Of Minnesota ,Minnesota ,Phoenix ,Arizona ,Chicago ,Illinois ,Orange County ,Matthew Mei ,Citius Pharma ,Myron Czuczman ,Ilanit Allen ,Greg Salsburg ,Veronika Bachanova ,Los Angeles ,University Of Minnesota Masonic Cancer Center ,Masonic Cancer Center ,Prnewswire Citius Pharmaceuticals Inc ,Exchange Commission ,Novartis Pharmaceuticals Corporation ,Cancer Center ,Securities Exchange ,Juno Therapeutics Inc ,Department Of Medicine ,National Cancer Institute ,Bristol Myers Squibb ,Kite Pharma Inc ,Gilead Sciences Inc ,Company Nasdaq ,Division Of Hematology ,Translational Genomics Research Institute ,Citius Pharmaceuticals Inc ,Minnesota Masonic Cancer Center ,Cancer Institute ,Biologics License Application ,Chief Medical Officer ,Minnesota Masonic Cancer ,Comprehensive Cancer Center ,Southern California ,Citius Pharmaceuticals ,Citius Oncology ,Securities Act ,Securities Exchange Act ,Annual Report ,Novartis Pharmaceuticals ,Kite Pharma ,Gilead Sciences ,Juno Therapeutics ,